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Few studies have specifically evaluated controller therapy in patients with mild persistent asthma. We used a
subgroup analysis to investigate the effects of montelukast, a potent cysteinyl leukotriene receptor antagonist, on
adult patients on the milder end of the asthma severity spectrum. We have identified seven double-blind,
randomized, placebo-controlled studies of adult patients with mild-to-moderate chronic asthma in which
montelukast was investigated. Subsets of patients with baseline forced expiratory volume in 1 sec (FEV1) 480%
and475% predicted or further restricted by less than daily rescue b-agonist use were included as four cohorts (A,
B, C, D), and ecacy measures, including change in FEV1 rescue-free days, b-agonist use, nocturnal awakenings
and blood eosinophil counts were evaluated. Cohorts A to D comprised 21%, 8%, 11%, and 4%, respectively, of
patients from these studies. Mean pretreatment FEV1 ranged from 81% to 84% predicted and daily b-agonist use
from 2?4 to 4?5 puffs day71 in the four cohorts. Pooled results demonstrated a treatment effect for montelukast
over placebo in all cohorts, for all endpoints. There was a significant improvement in FEV1 in montelukast-treated
patients (7–8% over baseline) compared with placebo (1–4% over baseline, between-group difference P40?02) for
all cohorts. Similarly, the percentage of rescue-free days increased substantially more with montelukast (22–30%)
than with placebo (8–13%). This subgroup analysis indicates that montelukast produced improvements in
parameters of asthma control in patients with milder persistent asthma that should be confirmed in additional
prospective trials.
Key words: mild persistent asthma; cysteinyl leukotriene receptor antagonist; montelukast; pulmonary function;
rescue-free day; treatment guidelines.
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Consensus guidelines for treating asthma recommend the
daily use of an anti-inflammatory agent as controller
therapy for patients with mild persistent asthma (step 2 of
asthma severity) (1,2). This population, defined as having
near-normal pulmonary function but active asthma symp-
toms, constitutes over 30% of patients with persistent
asthma (2). Low-dose inhaled corticosteroids are recom-
mended as the therapy of choice for these patients. Anti-
leukotriene therapy, as well as inhaled cromolyn orThis study was supported by a grant from Merck Research
Laboratories.
Received 3 July 2000 and accepted in revised form 30 January 2001.
Correspondence should be addressed to: Neil Barnes, Department
of Respiratory Medicine, London Chest Hospital, Bonner Road,
London E2 9JX, U.K. Fax: +44-20-8983-2279;
E-mail: neil.barnes@bartsandthelondon.nhs.uk
0954-6111/01/050379+08 $35?00/0nedocromil and sustained-release theophylline, are consid-
ered alternatives (1,2).
Asthma treatment guidelines are based on a review of the
available published evidence and are guided by expert
opinion. No studies have been published that use Global
Initiative for Asthma (GINA) or National Asthma Educa-
tion and Prevention Program (NAEPP) guidelines for the
definition of mild persistent asthma. Most large, rando-
mized, controlled studies of anti-asthma agents have
enrolled patients with a spectrum of disease, typically
mild-to-moderate or moderate-to-severe (3–10). In the few
studies that have evaluated therapies in patients with mild
asthma, the entry criteria for patients are consistent with
guidelines’ definition of moderate asthma (11,12), and most
of these studies are small (13–16) and not blinded or
placebo-controlled (17).
Our objective was to investigate the effects of montelu-
kast, a cysteinyl leukotriene receptor antagonist, on
patients with mild persistent asthma as defined, as best as
possible, by GINA or NAEPP guidelines. We evaluated the# 2001 HARCOURT PUBLISHERS LTD
380 N. BARNES ET AL.results of completed clinical trials to determine the degree
to which subsets of patients with mild asthma were
responsive to treatment with montelukast as measured by
a variety of asthma endpoints, including pulmonary
function and patient-reported parameters.
Materials and methods
TRIAL SELECTION
We searched the published literature using Medline and the
montelukast database to identify double-blind, rando-
mized, placebo-controlled trials enrolling adult patients
with mild-to-moderate chronic asthma, defined as forced
expiratory volume in 1 sec (FEV1) per cent predicted
between 50–90%, average use of at least 1–2 puffs day71
of rescue b-agonist during the run-in period, and improve-
ment in FEV1 of at least 12% after inhaled salbuterol in
which montelukast was administered at daily doses of at
least 10mg for at least 3 weeks. We found seven studies that
met these criteria (10,18–23).
The seven studies, designated as studies 1 to 7, varied in
duration and endpoints collected; however, any given
endpoint was collected in the same fashion for all studies.
Studies 2, 4, 6 and 7 (10, 20, 22, 23, respectively) collected
the following endpoints: asthma attacks, rescue b-agonist
use, blood eosinophil count, FEV1, nocturnal awakenings
and rescue-free days. Studies 1 and 3 (18, 19 respectively)
collected all endpoints except rescue-free days. Study 5 (21)
collected FEV1, rescue b-agonist use and blood eosinophil
count. Periodic measures of FEV1, made with a standard
spirometer (24), were recorded in the morning, approxi-
mately 12 h after the evening dose of study drug. Patients
completed a standard, validated, asthma-specific, daily
diary card (25) that included a record of rescue b-agonist
use, nights awake and asthma attacks. An asthma attack
was defined as an episode during which the patient sought
unscheduled medical care for asthma or required the use of
oral corticosteroids. Studies 1 and 3 included multiple doses
of montelukast (range 2–100mg); in the other five studies,
montelukast was administered once daily at bedtime as a
10-mg film-coated tablet. The frequency of clinic visits
varied from weekly (studies 1, 3 and 5) to every 3 weeks
(studies 2, 4 6, and 7) during treatment periods.
Patients were excluded from the individual studies if
there was a hospitalization for asthma within 3 months,
emergency room treatment for asthma within 1 month,
upper respiratory tract infection within 3 weeks, or
clinically significant sinus disease within 1 week prior to
the screening visit. At the time of enrollment into each
study, asthma therapy was restricted to short-acting inhaled
rescue b-agonist used on an as-needed basis.
From each individual study database, a standarized set of
patient demographic data, baseline clinical characteristics
and treatment variables, was collected. We selected four
cohorts of patients for inclusion in the analysis based on the
definition of mild persistent asthma contained in consensus
guidelines. Of those asthmatic patients with baseline FEV1
greater than 75% predicted, cohort A (391 montelukast/199placebo) had no limit on rescue b-agonist use and cohort B
(154 montelukast/70 placebo) had rescue b-agonist use less
than daily. Of those patients with baseline FEV1 greater
than 80% predicted, cohort C (201 montelukast/99
placebo) had no limit on rescue b-agonist use and cohort
D (75 montelukast/42 placebo) had rescue b-agonist use
less than daily. Consideration was given to strictly applying
the consensus guidelines definition of mild asthma which
would have included minimal daytime, night-time symp-
toms and normal peak flow. However, the seven studies
were designed prior to the most recent GINA or NAEPP
guidelines and these variables were not collected in all
studies. Furthermore, it was not possible to precisely align
the analysis to the guidelines’ definition of mild asthma
since this would have resulted in too few patients to
perform a meaningful analysis. We therefore evaluated two
parameters by which to judge asthma severity, namely,
baseline FEV1 per cent predicted and frequency of rescue b-
agonist use. Cohort A included patients who had, at
baseline, an FEV1 of475% of predicted value. We further
limited this subset, as cohort B, by including only those
patients who used rescue b-agonist therapy less frequently
than daily. For cohort C we restricted the baseline FEV1
per cent predicted level to 480%, irrespective of b-agonist
use, and in cohort D, also limited the rescue b-agpmost use
to less than daily. Patients who were receiving any other
chronic asthma therapy during the trial (for example,
inhaled corticosteroids or theophylline) were excluded from
all cohorts.
STATISTICAL ANALYSIS
We analysed endpoints that had been reported in the
individual studies, as well as a new endpoint: the percentage
of rescue-free days during treatment. A rescue-free day was
defined as a day during which a patient used no rescue b-
agonist or oral corticosteroid and had no unscheduled
asthma-related physician care. This endpoint has been
described for a small study enrolling only patients with mild
persistent asthma in which it showed significant respon-
siveness to treatment (26).
Data from each study were included in the pooled
analysis if the relevant endpoint was measured during the
study. Data on FEV1, rescue b-agonist use, and blood
eosinophil count were collected in all studies, and data on
nocturnal awakenings and asthma attacks in all but study
5. The rescue-free day endpoint was calculated from studies
in which both b-agonist and oral corticosteroid use were
collected, namely, studies 2, 4, 6 and 7. For each endpoint,
we included data from patients with a baseline and at least
one on-treatment value. Patients with baseline use of50?5
puffs day71 of rescue b-agonist were excluded from the
analysis of per cent change from baseline in total daily
rescue b-agonist use. Patients receiving montelukast at a
dose of 510mg (the labelled dose) were excluded from all
analyses.
For all endpoints except asthma attacks, treatment
comparisons between the placebo and montelukast treat-
ment groups were based on pairwise testing using an
TABLE 1. Asthma measurements at baseline
Cohort A Cohort B Cohort C Cohort D
Placebo Montelukast Placebo Montelukast Placebo Montelukast Placebo Montelukast
No. of patients 199? 391? 70? 154? 99? 201? 42? 75?
FEV1 (l) 2?92 (0?63) 2?89 (0?65) 3?00 (0?66) 2?91 (0?63) 3?00 (0?65) 3?01 (0?69) 3?05 (0?65) 3?08 (0?68)
FEV1 (% predicted) 81?(4) 81?(5) 81?(4) 81?(5) 84?(4) 84?(4) 84?(4) 84?(6)
b-agonist reversibility (%) 22?(8) 22?(9) 21?(9) 21?(8) 20?(8) 20?(8) 19?(9) 19?(8)
b-agonist use (puffs day71) 4?4 (3?3) 4?2 (2?8) 2?2 (1?2) 2?6 (1?6) 4?3 (3?7) 4?2 (2?6) 2?1 (1?2) 2?6 (1?4)
b-agonist use (days per week) 6?3 (1?4) 6?4 (1?1) 4?9 (1?6) 5?3 (1?3) 6?1 (1?4) 6?4 (1?1) 5?0 (1?5) 5?3 (1?3)
Nocturnal awakenings (nights per week) 3?1 (2?5) 2?9 (2?5) 2?5 (2?0) 2?3 (1?9) 2?9 (2?4) 2?8 (2?4) 2?6 (2?1) 2?4 (2?0)
Values are mean (SD).
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382 N. BARNES ET AL.analysis of covariance (ANCOVA) model with factors for
protocol and treatment. Baseline FEV1 values and baseline
FEV1 reversibility (after b-agonist) were included in the
model as covariates for the analysis of FEV1. For endpoints
other than FEV1, the corresponding baseline value was
included in the model as a covariate. A two-sided Fisher’s
exact test was used to compare the rates of asthma attacks
in the placebo and montelukast groups during treatment.
We evaluated individual study results for the four largest
studies (studies 2, 4, 6 and 7) for patients in cohort A and
the pooled study data for all cohorts.
Results
PATIENTS
Defining the patient cohort on the basis of baseline FEV1
alone, cohorts A and C, resulted in populations comprising
21% (590/2771) and 11% (300/2771), respectively, of all
patients enrolled in the placebo and montelukast treatment
groups of the seven studies. Further restricting the analysis
to patients who also used inhaled rescue b-agonist less than
daily, cohorts B and D reduced the population to 8% (224/
2771) and 4% (117/2771), respectively, of patients. Patients
included in cohort A from each of studies 1, 3 and 5
numbered 35 or fewer; those from each of studies 2, 4, 6
and 7 numbered 119 or more.
Baseline demographic characteristics and measures of
asthma severity were similar for the montelukastFIG. 1. Least square mean difference between montelukast and
per cent change from baseline of ecacy endpoints for patients
studies and pooled results from all seven studies are shown. Per
use (c). Change from baseline in percentage of rescue-free days (b
95% CI based on least square mean difference between treatmeand placebo treatment groups of each cohort (Table 1).
The mean age in all treatment groups was 30–33
years (range 15–77 years). The majority of patients in
each treatment group of the four cohorts were women
(56–64%) and most patients were white (68–81%). From 79
to 86% of patients in each treatment group reported a
history of allergic rhinitis. Baseline FEV1 averaged 81%
predicted in cohorts A and B and 84% predicted in cohorts
C and D.
Efficacy
The treatment differences between montelukast and place-
bo in each of the four largest studies (studies 2, 4, 6 and 7)
(for patients in cohort A) are shown in Fig. 1. The effect of
montelukast was consistent across these individual studies
for all endpoints.
Pooled data for the four cohorts (treatment difference
and 95% confidence interval) are summarized in Table 2.
Montelukast produced greater improvements than placebo
in all parameters, including FEV1, rescue b-agonist use,
nocturnal awakenings and rescue-free days, among patients
in all cohorts. Patients receiving montelukast experienced
significantly greater improvement in pulmonary function,
as measured by per cent change from baseline in FEV1 than
did patients receiving placebo (Table 2, Fig. 2). In the
montelukast group, the mean FEV1 increased from 6?8%
(cohort D) to 8?0% (cohort A); in the placebo group, the
mean FEV1 increased from 1?4% (cohort D) to 4?0%placebo treatment groups (and 95% CI) in change or
in cohort A. Results for each of the four largest individual
cent change from baseline in FEV1 (a) and rescue b-agonist
), nocturnal awakenings (d) and blood eosinophil count (e).
nts from ANCOVA model.
TABLE 2. Active treatment period changes for ecacy endpoints: pooled study results for patients in cohorts A, B, C, and D
Mean change or % change from baseline (SEM)
Placebo Montelukast Difference (95% CI) P-value
FEV1 (% change)
Cohort A 1?52 (0?85) 7?95 (0?59) 5?91 (3?94 to 7?89) 50?001
Cohort B 3?96 (1?24) 7?26 (0?79) 3?34 (0?60 to 6?08) 0?017
Cohort C 1?68 (1?12) 7?72 (0?73) 5?90 (3?38 to 8?42) 50?001
Cohort D 1?41 (1?58) 6?79 (1?02) 5?08 (1?66 to 8?50) 0?004
b-agonist puffs day71 (% change)
Cohort A 74?90 (3?47) 731?98 (2?58) 726?40 (735?21 to 717?58) 50?001
Cohort B 79?41 (7?48) 736?54 (5?14) 723?36 (741?42 to 75?31) 0?011
Cohort C 79?44 (5?14) 729?20 (3?51) 719?97 (732?12 to 77?82) 0?001
Cohort D 74?86 (10?70) 730?29 (7?53) 722?01 (747?46 to 3?45) 0?089
Nocturnal awakenings, nights per week (change)
Cohort A 70?35 (0?12) 71?08 (0?09) 70?75 (71?02 to 70?48) 50?001
Cohort B 70?62 (0?18) 70?99 (0?13) 70?48 (70?81 to 70?15) 0?005
Cohort C 70?50 (0?14) 71?01 (0?13) 70?54 (70?90 to 70?18) 0?003
Cohort D 70?55 (0?24) 70?87 (0?17) 70?41 (70?88 to 0?66) 0?088
Percentage of rescue-free days (change)
Cohort A 9?59 (0?24) 25?02 (1?68) 14?02 (8?67 to 19?37) 50?001
Cohort B 8?00 (4?02) 30?06 (3?04) 16?92 (7?03 to 26?82) 50?001
Cohort C 12?57 (2?96) 22?03 (2?31) 8?64 (1?05 to 16?23) 0?026
Cohort D 9?75 (5?07) 23?93 (4?42) 11?13 (72?25 to 24?52) 0?102
Eosinophil count, cells ml71 (change)
Cohort A 0?(11) 750?(10) 760?(790 to 730) 50?001
Cohort B 0?(18) 740?(16) 750?(790 7 to 10) 0?019
Cohort C 10?(15) 750?(14) 770?(7100 to 740) 50?001
Cohort D 0?(22) 740?(25) 770?(7120 7 to 20) 0?006
Difference between treatments is least square mean. 95% CI based on least square mean difference between treatments from
ANCOVA model.
MONTELUKAST IN MILD PERSISTENT ASTHMA 383(cohort B). Similarly, the percentage of rescue-free days
increased substantially more with montelukast (22–30%)
than with placebo (8–13%) in all cohorts.
The rate of asthma attacks was 3?1% in the montelukast
group of cohort A as compared with 8?8% in the placebo
group, for a difference of 5?6% [95% confidence interval
(CI) 1?3–10?0%; P=0?008]. Asthma attacks were infre-
quent in the milder cohorts B, C and D and were not
meaningfully different between the treatment groups.
In all cohorts, for the pooled study results, treatment
with montelukast caused a significant reduction in blood
eosinophil count compared with placebo (Table 2, Fig. 2).
Discussion
This analysis shows that montelukast provided significant
improvement in multiple parameters of asthma control in
patients with mild persistent asthma selected from seven
clinical trials. The pooled study results show substantial
positive treatment effects of montelukast, compared with
placebo, for all evaluated endpoints in patients identified as
having mild persistent asthma on the basis of FEV1 alone,as well as those selected by FEV1 and limited rescue
b-agonist use.
None of the studies included in this subanalysis was
designed to look specifically at patients with mild persistent
asthma. However, we believe it was valid to pool data from
these seven studies because all were randomized, placebo-
controlled studies enrolling patients of similar ages who
received therapeutically equivalent doses of montelukast.
We combined data for patients receiving daily doses of
montelukast of 10mg or more because the labelled dose of
montelukast is 10mg, the dose-response curve above 10mg
is flat and the drug has a wide safety margin (18,19).
Because the studies were designed to have different
durations, we analysed the treatment period average for
each ecacy endpoint. This strategy is appropriate, as
montelukast has a rapid onset of action and the treatment
response over time is relatively stable (10).
We selected patients whose asthma severity approxi-
mated that of patients with mild persistent asthma
according to the consensus asthma treatment guidelines
(1,2). Patients with mild persistent asthma differ from those
with more severe disease in that they have, by definition,
essentially normal pulmonary function between asthma
exacerbations. However, they do continue to experience
FIG. 2. Mean (+SEM) change or per cent change from baseline for patients in cohorts A, B, C and D, receiving placebo (open
bar) or montelukast (shaded bar) at a dosage of 510mg once daily. (a) FEV1; (b) percentage of rescue-free days; (c) b-
agonist use (as puffs day71); (d) nights awake (nights per week); (e) blood eosinophil count (cells ml71). *P40?05,
**P40?01, ***P40?001 for comparison between the montelukast and placebo groups.
384 N. BARNES ET AL.asthma symptoms or activity limitation, or both, on a
persistent by infrequent basis. For this reason we analysed
four cohorts of patients, two identified solely on the basis of
near-normal lung function (cohorts A and C), and two on
the basis of lung function as well as frequency of rescue
b-agonist use (at least 1 day per week, but not daily; cohorts
B and D). In fact, severity assessed by the mean baseline
FEV1 values did not distinguish between cohorts A and B
(both *81% predicted) or cohorts C and D (both *84%
predicted). The milder patients in cohort B and D were
differentiated from patients in cohorts A and C in that theyused less rescue b-agonist, on fewer days per week and
awoke less during the night. Previous work has shown that
the correlation between lung function and symptoms or
rescue medication use is poor (27,28). These observations
support asthma treatment guideline recommendations (1,2)
and argue for the use of multiple parameters, rather than
lung function alone, to define and monitor asthma severity.
Given that parameters of pulmonary function, such as
FEV1, are in the normal range in patients with mild
persistent asthma, pulmonary function may not be an ideal
endpoint for evaluating therapy as there is little room for
MONTELUKAST IN MILD PERSISTENT ASTHMA 385improvement. It is of interest, therefore, that improvement
in airway function was observed with montelukast therapy
in all four mild cohorts. Mean FEV1 values rose by 6?8% or
more in all montelukast-treated groups.
Results of other studies enrolling patients with mild
persistent asthma have been variable with regard to the
effects of treatment on pulmonary function. Juniper et al.
(13) found that asthma symptoms, bronchodilator use
and number of asthma exacerbations improved significantly
during 1 year of inhaled budesonide therapy, but
there was no change in FEV1. This could be, in part, the
authors speculate, because the mean baseline FEV1 was
90% predicted. Similarly, in studies by Wallin et al. (29)
and Hughes et al. (26) of patients with baseline
FEV1 488% predicted, treatment with inhaled fluticas-
one, formoterol or budesonide caused little or no
change in FEV1. In the latter study, patients did experience
significant reduction in the use of b-agonist and had
more rescue-free days with treatment. However, in other
studies of patients with mild asthma, significant improve-
ments in FEV1, often in conjunction with improvements
in asthma symptoms, were recorded with therapy
(14–17,30,31).
Measures of clinical outcomes other than FEV1 are
useful in evaluating treatment response for patients with
mild persistent asthma. In the present study, we found that
the percentage of rescue-free days, a measure representing
freedom from asthma attack as well as no need for reliever
therapy, rose substantially during montelukast treatment
relative to the modest increases observed in the placebo
group. Similar improvements were seen with decreased use
of rescue b-agonist and decreased nocturnal awakenings in
the montelukast groups of all cohorts. Asthma attacks were
reduced in cohort A by montelukast, compared with
placebo, but occurred at a lower rate in the milder cohorts
B, C, and D and were not different between treatment
groups. Asthma attacks are more likely to occur in patients
with more severe disease.
One of the principle reasons for the recommendation to
treat patients with mild persistent asthma with a daily
controller therapy is the observation that airway inflamma-
tion is present in these patients (32) and requires treatment.
Reductions in blood eosinophil counts, although an
indirect measure of anti-inflammatory effects, are evident
with montelukast therapy and are similar quantitatively to
those seen with inhaled corticosteroid therapy (20). In the
present analysis, blood eosinophil counts fell significantly,
compared with placebo, in patients on montelukast in all
four cohorts. These findings suggest that the eosinophil
lowering effects of montelukast are present even in patients
with mild disease.
The effects of another leukotriene receptor antagonist,
zafirlukast, have been examined in exploratory subset
analyses of combined results from four placebo-controlled
studies (33). Treatment effects of zafirlukast on asthma
symptoms or rescue b-agonist use were similar in subgroups
of patients stratified by baseline severity of disease,
although effects were more pronounced in patients with
increased severity of asthma, as defined by baseline
pulmonary function.There are clearly limitations to our current analysis. The
number of patients with mild persistent asthma, as defined
by FEV1 and use of rescue b-agonist, was small in each of
the seven studies. Notably, these patients had more
nocturnal symptoms and awakenings than defined by
guidelines for patients with mild persistent asthma, who
should have nocturnal symptoms more than two times per
month by one or less times per week (1,2). Although these
patients were therefore not strictly compliant with the
guideline definition of mild asthma, they nonetheless had
significant improvement in nocturnal symptoms with
montelukast treatment.
In conclusion, montelukast produced significant im-
provement in asthma symptoms and the percentage of
rescue-free days, as well as better pulmonary function, in
this analysis from completed clinical studies of patients with
persistent asthma and near-normal lung function. The
patients in this analysis approximated those described in
international guidelines as having mild asthma. These
retrospective results support the presence of clinical effects
of montelukast in patients with persistent disease on the
milder end of the asthma severity spectrum. Further
prospective studies are needed to confirm these results
and better characterize the response to montelukast and
other drugs in patients with mild persistent asthma.
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